ZEVEX Reports Revenue Growth and Improving Net Income for Second Quarter 2005

ZEVEX International Inc. (NASDAQ: ZVXI) reported
financial results for the three and six months ending June 30, 2005.
   Net income for the second quarter ending June 30, 2005, was
$168,468, or $0.05 per share, compared with net income of $192,892, or
$0.06 per share, for the same period of 2004. For the six-month period
ending June 30, 2005, net income was $213,621, or $0.06 per share,
compared with $401,673, or $0.12 per share, for the same period in
2004.
   Revenue for the second quarter ending June 30, 2005, increased
nine percent to $6.8 million, compared with $6.2 million for the
second quarter of 2004. For the six-month period ending June 30, 2005,
revenue grew by three percent to $12.8 million compared with $12.4
million for the same period in 2004.
   ZEVEX CEO and President David McNally said, "We are encouraged by
the sequential progress we are making this year in improving our
financial performance. Both revenue and earnings increased over the
first quarter of this year. Revenue for the second quarter improved in
both our Applied Technology and Therapeutics divisions. Applied
Technology revenue increased 11 percent over the second quarter of
last year, led by sales of complete systems, ultrasonic sensors and
handpieces that we produce for a number of medical companies.
Therapeutics revenue increased seven percent over the second quarter
of last year, primarily due to record unit sales of enteral feeding
pumps, and, notably, the new EnteraLite(R) Infinity(TM) model.
   "We are well positioned for an even stronger second half, led by
sales of enteral feeding pumps and disposable devices in connection
with our agreement with Numico," McNally concluded.
   Gross profit for the second quarter declined to 36 percent
compared with 39 percent in the same quarter of 2004, primarily due to
the product mix delivered during the quarter. In particular, the
results for the second quarter of 2004 included $193,000 more in
relatively high-margin engineering service revenue. Further, the
company made a $67,000 adjustment for obsolete inventory during the
second quarter of 2005. Without these factors, gross profit related to
product sales was approximately 36 percent for both quarters. For the
first six months of 2005, gross profit declined to 36 percent compared
with 38 percent in the first six months of 2004, due to these same
factors.
   Operating expenses declined as a percent of sales to 33 percent
for the second quarter of 2005 compared with 35 percent for the second
quarter of 2004. Selling, general and administrative expenses declined
to 30 percent of sales in the second quarter of 2005 compared with 32
percent for the same period of 2004, a result of the company's
emphasis on budget control. Research and development expenses were
higher in the second quarter of 2005 at nearly four percent of sales
compared with three percent of sales for the same period of 2004.
   For both the six-month periods ended June 30, 2005, and June 30,
2004, operating expenses were approximately 34 percent of sales.
Selling, general and administrative expenses were approximately 30
percent of sales for both periods. R&D expenditures were approximately
four and one-half percent of sales for the two comparable periods.

   Conference Call

   ZEVEX International Inc. invites all those interested to join the
ZEVEX management team for its earnings conference call for the second
quarter ended June 30, 2005. The call will be held Thursday, Aug. 4,
2005, at 4:30 p.m. EDT (3:30 p.m. Central, 2:30 p.m. Mountain, 1:30
p.m. Pacific). The telephone numbers for the call are as follows:

   Domestic: 800-257-6566
   International: 303-262-2139

   A live webcast and a rebroadcast of the conference call will be
available on the company's Web site at www.zevex.com and
www.streetevents.com. To listen to the live broadcast, please enter
the site 10-15 minutes prior to the call in order to download any
necessary software, and then click on the "Webcast" icon on the ZEVEX
home page to access the call. The webcast will be archived on both
sites. There is no other replay access to the call.

   About ZEVEX International

   ZEVEX International Inc. (www.zevex.com), founded in 1986, engages
in the business of designing, manufacturing and distributing medical
devices through its divisions and subsidiary. The Therapeutics
division manufactures and markets enteral nutrition delivery devices.
The Applied Technology division designs and manufactures advanced
medical components and systems for medical technology companies.

   Forward-Looking Statements

   Statements made in this press release, including those relating to
anticipated profit growth and other statements regarding future
performance, are forward looking and are made pursuant to the safe
harbor provisions of the Securities Litigation Reform Act of 1995.
Such statements involve risks and uncertainties that may cause actual
results to differ materially from those set forth in these statements.
Among other things, the company's efforts to improve its sales and
margins in its core businesses may not be effective or such efforts
could be more difficult or expensive than the company currently
anticipates. Further, the company could experience difficulties in its
contract manufacturing process that could delay the receipt of
anticipated revenue. In addition to the foregoing, the economic,
competitive, governmental, technological and other factors identified
in the company's filings with the Securities and Exchange Commission,
including the Form 10-K for the year ended Dec. 31, 2004, may cause
actual results or events to differ materially from those described in
the forward-looking statements in this press release.

                       ZEVEX INTERNATIONAL INC.
                     CONSOLIDATED INCOME STATEMENT

-0-
*T
                       Three Months Ended        Six Months Ended
                            June 30,                 June 30,
                        2005        2004         2005         2004
                     (unaudited) (unaudited) (unaudited)  (unaudited)

Revenue:
  Product Sales      $6,645,727  $5,878,725  $12,527,181  $11,993,257
  Engineering
   Services             151,926     345,272      254,636      439,444
                     ----------- ----------- ------------ ------------
  Total Revenue       6,797,653   6,223,997   12,781,817   12,432,701

  Cost of Sales       4,329,168   3,793,241    8,126,827    7,675,649
                     ----------- ----------- ------------ ------------
Gross Profit          2,468,485   2,430,756    4,654,990    4,757,052
Operating Expenses:
  Selling, General
   and
   Administrative:    2,011,290   2,013,277    3,801,669    3,701,424
  Research and
   Development:         243,972     179,115      565,628      565,643
                     ----------- ----------- ------------ ------------
Total Operating
 Expenses             2,255,262   2,192,392    4,367,297    4,267,067
Operating Income        213,223     238,364      287,693      489,985
Other Income
 (Expense):
  Interest and Other
   Income                13,426       3,070       16,555        4,856
  Interest Expense      (58,181)    (48,542)     (87,992)     (89,553)
                     ----------- ----------- ------------ ------------
Income Before Income
 Taxes                  168,468     192,892      216,256      405,288
Provision for Income
 Taxes                       --          --       (2,635)      (3,615)
                     ----------- ----------- ------------ ------------
Net Income             $168,468    $192,892     $213,621     $401,673
                     =========== =========== ============ ============
Basic Net Income Per
 Share                    $0.05       $0.06        $0.06        $0.12
                     =========== =========== ============ ============
Weighted Average
 Shares Outstanding   3,405,322   3,400,964    3,403,155    3,400,964
                     =========== =========== ============ ============
Diluted Net Income
 Per Share:               $0.05       $0.06        $0.06        $0.12
                     =========== =========== ============ ============
Diluted Weighted
 Average Shares
 Outstanding          3,506,609   3,438,380    3,510,118    3,448,263
                     =========== =========== ============ ============
*T

                       ZEVEX INTERNATIONAL INC.
                      CONSOLIDATED BALANCE SHEET

-0-
*T
                                                June 30,     Dec. 31,
                                                  2005         2004
                   ASSETS                     (unaudited)

Current assets
  Cash and cash equivalents                     $225,858     $212,859
  Designated cash for sinking fund payment
   on industrial development bond                 46,622       96,042
  Accounts receivable, net of allowances for
   doubtful accounts of $158,000 and $192,000  4,311,949    3,563,436
  Other receivable                                    --       35,500
  Inventories                                  4,087,300    4,584,755
  Marketable securities                           37,800       29,250
  Prepaid expenses and other current assets      135,531      149,690
                                             ------------ ------------
  Total current assets                         8,845,060    8,671,532

  Property and equipment, net                  4,407,147    4,345,942
  Patents, trademarks and other intangibles,
   net                                           340,252      335,244
  Goodwill, net                                4,048,264    4,048,264
                                             ------------ ------------
  Total assets                               $17,640,723  $17,400,982
                                             ============ ============

    LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
  Accounts payable                            $1,428,532   $1,949,618
  Other accrued liabilities                      736,505      606,734
  Bank line of credit                            517,405           --
  Income taxes payable                             2,005        2,005
  Current portion of industrial development
   bond                                          100,000      100,000
  Current portion of other long-term debt         54,712       53,246
                                             ------------ ------------
  Total current liabilities                    2,839,159    2,711,603

  Industrial development bond                  1,100,000    1,200,000
  Other long-term debt                           738,635      766,362

Stockholders' equity
  Common stock; $.001 par value, 10,000,000
   authorized shares, 3,444,704 issued and
   3,405,471 outstanding at June 30, 2005, and
   Dec. 31, 2004                                   3,445        3,440
  Additional paid-in capital                  16,308,188   16,290,452
  Unrealized gain on marketable securities        (9,975)     (18,525)
  Treasury stock, 39,233 shares (at cost) at
   June 30, 2005, and Dec. 31, 2004              (89,422)     (89,422)
  Accumulated deficit                         (3,249,307)  (3,462,928)
                                             ------------ ------------
  Total stockholders' equity                  12,962,929   12,723,017
                                             ------------ ------------
  Total liabilities and stockholders' equity $17,640,723  $17,400,982
                                             ============ ============
*T